Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and SBRT for Unresectable Pancreatic Adenocarcinoma
NCT01146054Phase 2Completed
- Sponsor
- Stanford University
- Start
- Oct 2009
- Primary completion
- Oct 2013
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Stanford University. Primary endpoint: Grade 2 or Greater Gastrointestinal Toxicity at 1 year. Started Oct 2009; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01146054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01146054.